PureTech Health PLC Akili Adds Award-Winning Marketing Leader as CMO
07 October 2020 - 11:03PM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
07 October 2020
7 October 2020
PureTech Health plc
PureTech Founded Entity Akili Announces Appointment of Chief
Marketing Officer
Meghan Rivera Brings Strong Track Record of Award-Winning
Disruptive Healthcare Launch Experience
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Akili, today announced the appointment of Meghan Rivera to the role
of chief marketing officer. In the newly created position, Rivera
will lead marketing and sales of EndeavorRx(TM) , the company's
first commercial product, which was granted FDA clearance in June
2020.
The full text of the announcement from Akili is as follows:
Akili Announces Appointment of Chief Marketing Officer
Meghan Rivera Brings Strong Track Record of Award-Winning
Disruptive Healthcare Launch Experience
BOSTON - October 7, 2020 - Akili today announced the expansion
of the company's executive team with the appointment of Meghan
Rivera to the role of chief marketing officer. In the newly created
position, Rivera will lead marketing and sales of EndeavorRx, the
company's first commercial product, which was granted FDA clearance
in June 2020.
"Meghan is an innovative leader with a history of executing
disruptive marketing and commercial strategies," said Eddie
Martucci, PhD, chief executive officer of Akili. "As we make the
transition to a commercial organisation at Akili, her focus on
results and passion for bringing the voice of the customer to
healthcare will serve us well as we continue to push the boundaries
of medicine and create amazing experiences for patients and their
families."
Rivera brings to Akili a strong digital marketing background
with experience building diverse, high performing sales and
marketing teams . She joins Akili from AMAG Pharmaceuticals, Inc.
where she ran the company's women's health business. Prior, Rivera
was responsible for marketing and customer experience at Boehringer
Ingelheim where she received the company's Outstanding Marketing
Innovation award, and she held senior roles at a number of notable
healthcare marketing agencies. Throughout the course of her career
of more than 20 years, Rivera has been recognised as an industry
thought leader, including being named the 2012 "Rising Star" by the
Healthcare Women Association, the 2015 PM360 ELITE Transformational
Leader and being inducted in 2018 into the MM&M "Hall of
Femme."
"I'm thrilled to join the team at Akili where we are defying
convention and changing the way the world experiences medicine,"
said Rivera. "EndeavorRx(TM) represents the next generation of
digital therapeutics, but it is only the beginning. I look forward
to our continuing to challenge the status quo in healthcare and
helping and connecting with patients in ways we never before
imagined."
About Akili
Akili is combining scientific and clinical rigour with the
ingenuity of the tech and entertainment industries to challenge the
status quo of medicine. Akili has pioneered the development of
video game-based digital medicine to improve cognitive function.
Akili's flagship product, EndeavorRx, is a prescription digital
treatment to address inattention in children with attention deficit
hyperactivity disorder (ADHD). Akili's patented technology serves
as the foundation of its products and is designed to directly
activate the networks in the brain responsible for cognitive
function. Driven by Akili's belief that effective medicine can also
be fun and engaging, Akili's treatments are delivered through
captivating action video game experiences that drive engagement and
compliance. For more information, please visit AkiliInteractive.com
.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have received US Food and Drug Administration (FDA) clearance
and European marketing authorisation. All of the underlying
programmes and platforms that resulted in this pipeline of product
candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMZMGGZVNGGZZ
(END) Dow Jones Newswires
October 07, 2020 08:03 ET (12:03 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024